BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yong MK, Lewin SR, Manuel O. Immune Monitoring for CMV in Transplantation. Curr Infect Dis Rep 2018;20:4. [PMID: 29542023 DOI: 10.1007/s11908-018-0610-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Peña-Asensio J, Calvo H, Miquel J, Sanz-de-Villalobos E, González-Praetorius A, Torralba M, Larrubia JR. Model to predict on-treatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2022;55:1545-59. [PMID: 35224746 DOI: 10.1111/apt.16850] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Pongsakornkullachart K, Chayakulkeeree M, Vongwiwatana A, Kantakamalakul W, Skulratanasak P, Phoompoung P. QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country. Front Cell Infect Microbiol 2022;12:893232. [DOI: 10.3389/fcimb.2022.893232] [Reference Citation Analysis]
3 Gardiner BJ, Lee SJ, Robertson AN, Cristiano Y, Snell GI, Morrissey CO, Peleg AY, Westall GP. Real-world experience of Quantiferon®-CMV directed prophylaxis in lung transplant recipients. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.05.004] [Reference Citation Analysis]
4 Zu C, Xu Y, Wang Y, Zhang M, Zhao H, Fang X, Huang H, Hu Y. Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Current Oncology 2022;29:490-6. [DOI: 10.3390/curroncol29020044] [Reference Citation Analysis]
5 Munting A, Manuel O. Viral infections in lung transplantation. J Thorac Dis 2021;13:6673-94. [PMID: 34992844 DOI: 10.21037/jtd-2021-24] [Reference Citation Analysis]
6 Filippidis P, Vionnet J, Manuel O, Mombelli M. Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34854329 DOI: 10.1080/14787210.2022.2013808] [Reference Citation Analysis]
7 Godsell J, Chan S, Slade C, Bryant V, Douglass JA, Sasadeusz J, Yong MK. Cytomegalovirus in primary immunodeficiency. Curr Opin Infect Dis 2021;34:663-71. [PMID: 34608876 DOI: 10.1097/QCO.0000000000000797] [Reference Citation Analysis]
8 Karami S, Roshandel E, Ghaffari Nazari H, Hajifathali A, Tavakoli F, Parkhideh S. In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients. Virusdisease 2021;32:422-34. [PMID: 34631973 DOI: 10.1007/s13337-021-00728-w] [Reference Citation Analysis]
9 Jakharia N, Howard D, Riedel DJ. CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies. Curr Treat Options Infect Dis 2021;:1-18. [PMID: 34305463 DOI: 10.1007/s40506-021-00253-w] [Reference Citation Analysis]
10 Manuel O, Avery RK. Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity. Curr Opin Infect Dis 2021;34:307-13. [PMID: 34074879 DOI: 10.1097/QCO.0000000000000746] [Reference Citation Analysis]
11 Yong MK, Gottlieb D, Lindsay J, Kok J, Rawlinson W, Slavin M, Ritchie D, Bajel A, Grigg A. New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation. Intern Med J 2020;50:277-84. [PMID: 31403736 DOI: 10.1111/imj.14462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 García-Ríos E, Nuévalos M, Mancebo FJ, Pérez-Romero P. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients? Front Immunol 2021;12:657144. [PMID: 33968058 DOI: 10.3389/fimmu.2021.657144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhou X, Jin N, Chen B. Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation. Oncol Lett 2021;21:318. [PMID: 33692850 DOI: 10.3892/ol.2021.12579] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Wagner-Drouet E, Teschner D, Wolschke C, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Hilgendorf I, Klein S, Verbeek M, Ditschkowski M, Koch M, Lindemann M, Schmidt T, Rascle A, Barabas S, Deml L, Wagner R, Wolff D. Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics (Basel) 2021;11:312. [PMID: 33671952 DOI: 10.3390/diagnostics11020312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Grass S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Rascle A, Guldan H, Barabas S, Deml L, Wagner R, Wolff D. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica 2021;106:363-74. [PMID: 31879324 DOI: 10.3324/haematol.2019.229252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
16 Hofmann E, Sidler D, Dahdal S, Bittel P, Suter-Riniker F, Manuel O, Walti LN, Hirzel C. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature. Transpl Infect Dis 2021;23:e13515. [PMID: 33210830 DOI: 10.1111/tid.13515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Hellemans R, Abramowicz D. Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention. Nephrol Dial Transplant 2020:gfaa249. [PMID: 33280028 DOI: 10.1093/ndt/gfaa249] [Reference Citation Analysis]
18 Hellemans R, Wijtvliet V, Bergs K, Philipse E, Vleut R, Massart A, Couttenye MM, Matheeussen V, Abramowicz D. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options? Transpl Infect Dis 2021;23:e13467. [PMID: 32935909 DOI: 10.1111/tid.13467] [Reference Citation Analysis]
19 Healy ZR, Weinhold KJ, Murdoch DM. Transcriptional Profiling of CD8+ CMV-Specific T Cell Functional Subsets Obtained Using a Modified Method for Isolating High-Quality RNA From Fixed and Permeabilized Cells. Front Immunol 2020;11:1859. [PMID: 32983102 DOI: 10.3389/fimmu.2020.01859] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Khan SF, Yong MK, Slavin MA, Hughes P, Sasadeusz J. Very late‐onset cytomegalovirus disease with ganciclovir resistance >15 years following renal transplantation. Transpl Infect Dis 2021;23. [DOI: 10.1111/tid.13441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Houldcroft CJ, Jackson SE, Lim EY, Sedikides GX, Davies EL, Atkinson C, McIntosh M, Remmerswaal EBM, Okecha G, Bemelman FJ, Stanton RJ, Reeves M, Wills MR. Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay. Front Cell Infect Microbiol 2020;10:275. [PMID: 32670891 DOI: 10.3389/fcimb.2020.00275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Naik S, Vasileiou S, Aguayo-hiraldo P, Mukhi S, Sasa G, Martinez C, Krance RA, Gottschalk S, Leen A. Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation 2020;26:911-9. [DOI: 10.1016/j.bbmt.2020.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Fernández-Ruiz M, López-Medrano F, Aguado JM. Predictive tools to determine risk of infection in kidney transplant recipients. Expert Rev Anti Infect Ther 2020;18:423-41. [PMID: 32084326 DOI: 10.1080/14787210.2020.1733976] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 Stern A, Papanicolaou GA. CMV Prevention and Treatment in Transplantation: What's New in 2019. Curr Infect Dis Rep 2019;21:45. [PMID: 31732823 DOI: 10.1007/s11908-019-0699-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
25 Lung T, Sakem B, Risch L, Würzner R, Colucci G, Cerny A, Nydegger U. The complement system in liver diseases: Evidence-based approach and therapeutic options. J Transl Autoimmun 2019;2:100017. [PMID: 32743505 DOI: 10.1016/j.jtauto.2019.100017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
26 Maffini E, Busca A, Costa C, Giaccone L, Cerrano M, Curtoni A, Cavallo R, Bruno B. An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol 2019;12:937-45. [PMID: 31423858 DOI: 10.1080/17474086.2019.1657399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Girmenia C, Lazzarotto T, Bonifazi F, Patriarca F, Irrera G, Ciceri F, Aversa F, Citterio F, Cillo U, Cozzi E, Gringeri E, Baldanti F, Cavallo R, Clerici P, Barosi G, Grossi P. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant 2019;33:e13666. [PMID: 31310687 DOI: 10.1111/ctr.13666] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
28 Kachaeva MV, Pilyo SG, Hartline CB, Harden EA, Prichard MN, Zhirnov VV, Brovarets VS. In vitro activity of novel derivatives of 1,3-oxazole-4-carboxylate and 1,3-oxazole-4-carbonitrile against human cytomegalovirus. Med Chem Res 2019;28:1205-11. [DOI: 10.1007/s00044-019-02365-x] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
29 Chen K, Cheng MP, Hammond SP, Einsele H, Marty FM. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv 2018;2:2159-75. [PMID: 30154125 DOI: 10.1182/bloodadvances.2018016493] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
30 Stanzani M, Lewis RE. Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease. J Fungi (Basel) 2018;4:E141. [PMID: 30572637 DOI: 10.3390/jof4040141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]